This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Prednisone in Chronic Rhinosinusitis Without Nasal Polyps

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2015 by Constanza J. Valdes, University of Chile.
Recruitment status was:  Recruiting
Sponsor:
Collaborator:
Sociedad Chilena de Otorrinolaringología, Medicina y Cirugía de Cabeza y Cuello
Information provided by (Responsible Party):
Constanza J. Valdes, University of Chile
ClinicalTrials.gov Identifier:
NCT02367118
First received: February 8, 2015
Last updated: June 2, 2015
Last verified: June 2015
  Purpose
The purpose of this study is to determine whether prednisone is effective in the treatment of chronic rhinosinusitis without nasal polyps in adult patients.

Condition Intervention Phase
Sinusitis Chronic Rhinosinusitis Drug: Prednisone Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Prednisone in Chronic Rhinosinusitis Without Nasal Polyps. A Double-blind, Randomized, Placebo-controlled Trial

Resource links provided by NLM:


Further study details as provided by Constanza J. Valdes, University of Chile:

Primary Outcome Measures:
  • Changes in Symptoms as measured by SNOT 22 questionnaire and visual analogue scale at 6 months [ Time Frame: Improvement in symptoms at the end (average of 25 days is expected) of the administration of prednisone (intervention), one month, three months and six months after the end of intervention compared to placebo ]
  • Change in Olfactory function as measured by "Sniffin'Sticks 12 tests" at 6 months [ Time Frame: Improvement in Olfactory function at the end (average of 25 days is expected) of the administration of prednisone (intervention), one month, three months and six months after the end of intervention compared to placebo ]
  • Change in Nasal patency as measured by Acoustic rhinometry and Rhinomanometry at 6 months [ Time Frame: Improvement in nasal patency at the end (average of 25 days is expected) of the administration of prednisone (intervention), one month, three months and six months after the end of intervention compared to placebo ]
  • Changes in Nasal endoscopy findings as measured by Lund-Kennedy score at 6 months [ Time Frame: Changes in nasal endoscopy findings at the end (average of 25 days is expected) of the administration of prednisone (intervention), one month, three months and six months after the end of intervention compared to placebo ]

Estimated Enrollment: 90
Study Start Date: June 2015
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Prednisone
Intervention: prednisone 5 mg tablets taken orally, in decreasing doses. Beginning with 6 tablets (30 mg) daily for 7 days, then 3 tablets (15 mg) daily for 7 days, then 1 tablet (5 mg) daily for 7 days. Total days of treatment: 21 days.
Drug: Prednisone
Placebo Comparator: Placebo
Intervention: placebo tablets taken orally (similar to prednisone), in decreasing doses. Beginning with 6 tablets daily for 7 days, then 3 tablets daily for 7 days, then 1 tablet daily for 7 days. Total days of treatment: 21 days.
Drug: Placebo

Detailed Description:

General Objective:

1. Compare clinical improvement in adult patients with chronic rhinosinusitis without nasal polyps (CRSsNP) through application of SNOT 22 questionnaire and visual analogue scale of symptoms, sniff test, acoustic rhinometry and rhinomanometry and nasal endoscopy using Lund-Kennedy score, after 6 months of follow-up after treatment prednisone or placebo plus standard medical treatment for 21 days.

Specific Objectives:

  1. Compare decreased in SNOT-22 questionnaire score and visual analog scale of symptoms after treatment with prednisone or placebo.
  2. Compare decreased in nasal endoscopy findings, through application of Lund-Kennedy score, after treatment with prednisone or placebo.
  3. Compare improvements in smell after treatment with prednisone or placebo.
  4. Determine whether there are differences in nasal permeability measured by rhinomanometry and acoustic rhinometry after treatment with prednisone or placebo.
  5. Determine whether there is a difference in the SNOT 22 questionnaire score, visual analogue scale of symptoms, score of smell and Lund-Kennedy score between CRSsNP patients and eosinophilia, and CRSsNP patients with normal eosinophils, receiving prednisone or placebo .
  6. Determine if there is a difference in the SNOT 22 questionnaire score, visual analogue scale of symptoms, score of smell and Lund-Kennedy score between CRSsNP patients with elevated total immunoglobulin E and CRSsNP patients with normal total immunoglobulin E, receiving treatment with prednisone or placebo.
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of CRSsNP as recommended European Position Paper on Rhinosinusitis and Nasal Polyps 2012

Exclusion Criteria:

  • Treatment with oral corticosteroids or topical corticosteroids the last 4 weeks.
  • Previous surgical treatment for CRSsNP
  • History of diabetes mellitus and / or glaucoma and / or decompensated hypertension and / or gastric ulcer.
  • Pregnancy.
  • History of cystic fibrosis, primary ciliary dyskinesia, immunodeficiency, allergic fungal sinusitis, nasal polyps, nasal tumors, hepatic or renal dysfunction.
  • Hypersensitivity to prednisone
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02367118

Contacts
Contact: Constanza J Valdes, MD 56-02-2575-3968 cjvaldes@gmail.com
Contact: Marcela A Veloz, MD 56-02-2575-3968 marceveloz@gmail.com

Locations
Chile
Hospital del Salvador Recruiting
Santiago, Region Metropolitana, Chile, 7600490
Contact: Constanza J Valdes, MD    56-02-2575-3968    cjvaldes@gmail.com   
Contact: Marcela A Veloz, MD    56-02-2575-3968    marceveloz@gmail.com   
Sub-Investigator: Nicole S Jimenez         
Sub-Investigator: Felipe Cardemil, MD         
Sponsors and Collaborators
University of Chile
Sociedad Chilena de Otorrinolaringología, Medicina y Cirugía de Cabeza y Cuello
Investigators
Study Director: Constanza J Valdes, MD University of Chile
Principal Investigator: Marcela A Veloz, MD University of Chile
  More Information

Publications:

Responsible Party: Constanza J. Valdes, MD, Professor Assistant University of Chile. Department of Otorhinolaryngology-Head and Neck Surgery., University of Chile
ClinicalTrials.gov Identifier: NCT02367118     History of Changes
Other Study ID Numbers: PRD- CRSsNP-1
Study First Received: February 8, 2015
Last Updated: June 2, 2015

Keywords provided by Constanza J. Valdes, University of Chile:
chronic rhinosinusitis without nasal polyps prednisone

Additional relevant MeSH terms:
Sinusitis
Nasal Polyps
Paranasal Sinus Diseases
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Polyps
Pathological Conditions, Anatomical
Prednisone
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents

ClinicalTrials.gov processed this record on June 23, 2017